ELLIPSE: Liraglutide Effective for Diabetes in Adolescents ELLIPSE: Liraglutide Effective for Diabetes in Adolescents
This is a ' practice-changing ' study, says the lead author, since ' metformin fails quickly as monotherapy in type 2 diabetes kids and insulin is the only second-line drug approved ' for these children.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 28, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Finally, another effective drug for kids and teens with type 2 diabetes
A new drug, liraglutide, will be “transformational” for youth with type 2 diabetes, according to new Yale-led research in the New England Journal of Medicine. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 28, 2019 Category: Universities & Medical Training Source Type: news
Efficacy and Safety of IDegLira in Older Patients With T2D Efficacy and Safety of IDegLira in Older Patients With T2D
IDegLira is an insulin degludec/liraglutide combination that has been shown to improve glycemic control in type 2 diabetes. Is it a safe and effective option for older patients?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Metformin vs. Victoza
Title: Metformin vs. VictozaCategory: MedicationsCreated: 12/19/2018 12:00:00 AMLast Editorial Review: 12/19/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 19, 2018 Category: Drugs & Pharmacology Source Type: news
Diabetes drug liraglutide linked to lower risk of cardiovascular events
(Karolinska Institutet) Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes& Endocrinology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2018 Category: International Medicine & Public Health Source Type: news
IBT Plus Liraglutide Boosts Weight Loss in Obese Patients
(MedPage Today) -- Adding pharmacotherapy also led to beneficial changes in appetite (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 15, 2018 Category: Endocrinology Source Type: news
Study: Diabetes drug also may reduce heart disease risk
Diabetes patients who take liraglutide to treat their sugar levels might also reduce risk for heart disease, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 27, 2018 Category: Consumer Health News Source Type: news
A New Player in Type 1 Diabetes Treatment?
Liraglutide: A New Player in Type 1 Diabetes Treatment? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 10, 2018 Category: General Medicine Source Type: news
Liraglutide: A New Player in Type 1 Diabetes Treatment? Liraglutide: A New Player in Type 1 Diabetes Treatment?
In a randomized, placebo-controlled trial, liraglutide added to insulin improved glycemic control and reduced weight and blood pressure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Novo's pioneering diabetes pill beats Victoza, Januvia in tests
COPENHAGEN (Reuters) - Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck& Co's Januvia and its own best-selling injectable treatment Victoza in tests. (Source: Reuters: Health)
Source: Reuters: Health - June 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Study offers new hope for the fight against genetically determined obesity
(University of Copenhagen The Faculty of Health and Medical Sciences) A large group of people with obesity have a genetic mutation that is causing their obesity. Common treatments for obesity only benefit these people to a limited extent, but now a new study conducted at the University of Copenhagen reveals that they can be treated effectively with the medicine liraglutide, which is a GLP-1 receptor agonist. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news
Liraglutide cost saving versus sitagliptin for T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
Xultophy Injection (Insulin Degludec and Liraglutide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2017 Category: Drugs & Pharmacology Source Type: news
Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza
Novo Nordisk (NYSE:NVO) said today that it inked a value-based contract for its Type II diabetes drug, Victoza, with pharmacy benefit manager Prime Therapeutics.
The agreement is part of Prime’s CareCentered Contract program. Under the terms of the deal, Prime will evaluate Victoza’s efficacy and will reimburse commercial clients if certain measures aren’t met, according to the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk inks outcomes-based contract with pharmacy benefit manager for Victoza appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news
Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news
